24 MIC testing using the BACTEC 960 MGIT system of 70 phylogenetically diverse, isoniazid-25 resistant clinical strains of Mycobacterium tuberculosis revealed a complex pattern of 26 overlapping MIC distributions. Whole-genome sequencing could explain most of the level of 27 resistance observed. The MIC distribution of strains with only inhA promoter mutations was 28 split by the current concentration that is endorsed by the Clinical Laboratory Standards 29
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In light of the continued selection and spread of drug-resistant tuberculosis, coupled with 32 the dearth of novel antibiotics, the question of whether low-level resistance can be 33 overcome by increasing the dose of a drug has become more urgent than ever (1). In 2018, 34 the World Health Organization (WHO) has formally endorsed this possibility for 35 moxifloxacin, whereby a dose of 800 mg/day can be used to treat low-level resistance to 36 this fluoroquinolone, although the corresponding clinical breakpoint has not been 37 recognized by the Clinical Laboratory Standards Institute (CLSI) (2-4). Conversely, for at least 38 15 years the position of CLSI has been to stratify resistance to the core drug isoniazid (INH) 39 into low-and high-level resistance by testing two concentrations of this drug, whereas WHO 40 has not endorsed this concept to date (5-7). Specially, the CLSI recommendation is to 41 include the following statement in the antimicrobial susceptibility testing (AST) reports of 42 strains that are only low-level resistant (i.e. that are resistant at the critical concentration 43 but not the higher breakpoint of INH): "A specialist in the treatment of [multidrug resistant 44 tuberculosis] should be consulted concerning the appropriate therapeutic regimen and 45 dosages" (3). However, WHO is in the process of reviewing its recommendation for INH and, 46 in its most recent manual for AST, has begun to stratify INH resistance on the genotypic 47 level but has not yet set corresponding breakpoints to align the phenotype (6). We 48 therefore set out to compare the phenotypic definitions of low-and high-level resistance by 49 CLSI with the genotypic stratification proposed by WHO. 50 To this end, we used the BC BACTEC Mycobacteria Growth Indicator Tube (MGIT) 51 960 system to conduct comprehensive MIC testing of a selected set of phylogenetically 52 diverse strains (70 INH resistant and 5 INH susceptible isolates, respectively) along with M. 53 tuberculosis H37Rv ATCC 27294 as control strain. Four serial two fold dilutions were 54 prepared from INH stock solution to provide a final test range of 0.016-0.25 g/ml for 55 susceptible and H37Rv strains, 0.25-4 g/ml for inhA promoter mutant isolates with or 56 without a concurrent inhA coding mutation, 1-16 g/ml for S315T/N mutant isolates and 4-57 64 g/ml for isolates with double mutations in katG and inhA promoter. The MGIT MIC was 58 defined as the lowest antibiotic concentration that completely inhibited the growth of MTB 59 when the control tube reached 400 growth unit. Whole Genome Sequencing (WGS) was 60 performed using Nextera-XT DNA kit to prepare paired-end-libraries and sequenced on 61 3 Illumina platform. Data analysis and SNPs calling were performed by MTBseq Pipeline (8) 62 (for additional details see supplementary materials). 63
The six susceptible controls had INH MICs of 0.03-0.06 g/ml ( Figure 1 and Table S2 ). 64
By contrast, resistant strains displayed a series of overlapping MIC distributions. Strains that 65 only had mutations that are interrogated by the WHO-endorsed genotypic AST assays (i.e. 66 the Hain GenoType MTBDRplus version 2 and Nipro NTM+MDRTB version 2) resulted in the 67 following three MIC distributions (9) . Strains that only had an inhA promoter changes or a 68 mutation at codon 315 of katG had non-overlapping MIC distributions of 0.25-2 g/ml and 69 4-16 g/ml, respectively. Strains with both mutations displayed MICs of 8-64 g/ml. The 70 variation in these distributions was likely largely due to the normal variation in MIC testing 71 (i.e. even in the same laboratory, a variation of plus or minus one dilution is inevitable, 72 which is further exacerbated by the variation in testing between laboratories). 73
The precise level of resistance cannot be predicted using the Hain and Nipro assays 74 alone because mutations that are not interrogated by these assays can increase the MICs. 75
To some extent, this could be overcome by using WGS data, provided that know mutation 76 or mutations with predictable effects were identified (i.e. the level of resistance could not 77 be fully explained even with WGS). For example, some, but not all, strains with loss-of-78 function mutations in katG had MICs of >64 g/ml (Figure 1) . Moreover, a C deletion 34 79 nucleotides upstream of the main transcriptional start site of inhA likely accounted for the 80 unusually high MIC of 64 g/ml for a katG S315N mutant (10). By contrast, another 81 mutation upstream of inhA at codon 203 of fabG1, which is known to result in the over-82 expression of inhA by creating an alternative promoter, did not appear to increase the MIC 83 above the level explained by the katG S315T mutation in the strain in question (i.e. 8 g/ml) 84 (11). Similarly, there was an almost complete overlap between the MIC distributions of 85 strains that harbor only inhA promoter mutations and those that had an additional inhA 86 coding mutation at codons 21, 94, or 194 (i.e. 0.25-2 g/ml compared with 0.5-2 g/ml). 87 MGIT MIC data from more laboratories are needed to define robust quality control 88 ranges/targets for INH and to quantify the effect of lab-to-lab variation on the MIC 89 distributions described in this study (12) . Assuming that our results are generalizable, 90 several conclusions can be drawn. To assess the treatment efficacy of the standard or 91 elevated dose of INH in the presence of a particular resistance conferring mutation, the 92 4 upper end of the MIC distribution of the specific mutation has to be considered (13) (14) (15) . For 93 strain with only inhA promoter mutations, this target concentration would be 1 or 2 g/ml 94 (i.e. at least 10 times higher than the current critical concentration of 0.1 g/ml (3, 6)). 95
Should pharmacokinetic/pharmacodynamic, drug penetration, and clinical outcome data 96 confirm that this target is achievable, it should be adopted as the clinical breakpoint as 97 opposed to the current CLSI concentration of 0.4 g/ml, which corresponds to 0.5 g/ml 98 using our dilution series (16, 17) . This would avoid splitting the MIC distribution of inhA 99 promoter mutants and would therefore reduce or eliminate their misclassification as high-100
level resistant because of the technical variation in AST, as would be the case with the CLSI 101 breakpoint. 102
One argument against setting a clinical breakpoint at 1 or 2 g/ml might be that it 103 would result in the misclassification of strains with both inhA promoter and coding 104 mutations as low-level resistant, as stressed in previous consensus statement (6, 18) . 105
However, two aspects should be borne in mind. First, only 3% (95% CI, 1-6%) of strains with 106 inhA promoter mutations in the -16 to -8 region that do not have katG mutations have 107 additional inhA coding mutations based on recent WHO population-level surveillance data 108 from seven countries (19) . Therefore, in most settings misclassifications of double mutants 109 would be rare compared with the increased ability to detect inhA promoter mutants with a 110 higher clinical breakpoint. Second, the effect of these coding mutations on the INH MIC and 111 thus clinical outcome is likely modest at worst, but more MIC data are needed for the 112 mutations at different inhA codons (20-23). Nevertheless, it might be advisable for countries 113 that conduct routine WGS to err on the side of caution by classifying these double mutants 114 as high-level resistant until clinical data to the contrary are available (in practice, however, it 115 would be challenging to conduct a sufficiently powered study to address this question as 116 these mutations are so rare Isoniazid MIC results stratified by known or likely resistance mutations in the coding region 135 of katG or inhA, or mutations that result in the overexpression of inhA. All of the latter 136 mutations are upstream of inhA, but "promoter" was used to highlight the subgroup of 137 these mutations (i.e. those in the -16 to -8 region upstream of the transcriptional start site 138 of the fabG1-inhA operon (24)) that can be detected by the WHO-endorsed Hain GenoType 139
MTBDRplus version 2 and Nipro NTM+MDRTB version 2 assays (all mutations interrogated 140 by these assays are shown in bold in the legend of the plot). 141 gWT=genotypically wild-type strains (i.e. strains without known resistance mutations); 142
LOF=loss-of-function mutation (i.e. insertion, deletion, or nonsense mutation). 143
